Angitia Biopharma to Present AGA2118 Osteoporosis Data at ASBMR 2024

Angitia Biopharmaceuticals, a global clinical-stage biotechnology firm, has announced that data from its ongoing research on AGA2118 for treating osteoporosis will be presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. The event will take place from September 27-30, 2024, in Toronto, Canada. The selected abstracts highlight both preclinical and clinical data for AGA2118, showcasing significant developments in osteoporosis treatment.

Osteoporosis is a widespread skeletal disease marked by low bone mass and the deterioration of bone tissue, leading to increased fragility and fracture risk. With an aging population, the disease has become a global health concern, particularly affecting older women. Despite the availability of approved therapies, there are still significant limitations in their efficacy and safety, leaving many severely osteoporotic individuals without effective treatment. This underscores the urgent need for new and improved osteoporosis therapies.

AGA2118 is a bispecific antibody that targets both Sclerostin and DKK1, two proteins that negatively regulate WNT signaling in osteoblasts and bone metabolism. By neutralizing these proteins, AGA2118 aims to enhance bone mineral density gains in patients with osteoporosis. Angitia Biopharmaceuticals owns the rights to this innovative bispecific antibody and is advancing its clinical development.

The presentations at the ASBMR Annual Meeting will cover various aspects of AGA2118's efficacy and safety. One oral presentation, scheduled for September 27, will discuss the results from a placebo-controlled, randomized study involving single and multiple doses of AGA2118. This study demonstrated that AGA2118 increases bone formation, decreases bone resorption, and leads to rapid gains in bone mineral density (BMD). Another oral presentation on September 29 will highlight how AGA2118 increased bone mass and strength in an ovariectomized cynomolgus monkey model.

In addition to the oral presentations, two poster sessions will provide further insights into AGA2118's long-term effects and pharmacokinetics. One poster, presented on September 27-28, will discuss the long-term impact of AGA2118 on bone formation and resorption markers in cynomolgus monkeys. Another poster, scheduled for September 28, will focus on the preclinical and clinical pharmacokinetics of AGA2118, emphasizing its potential as a treatment for osteoporosis.

Angitia Biopharmaceuticals is dedicated to discovering and developing innovative treatments for serious musculoskeletal diseases. Currently, the company is studying three biologic product candidates targeting osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team's extensive experience in novel drug development, Angitia aims to address significant unmet medical needs with groundbreaking therapies.

In summary, the upcoming presentations at the ASBMR Annual Meeting will showcase the promising potential of AGA2118 in treating osteoporosis. With its unique mechanism of action and positive preclinical and clinical data, AGA2118 represents a significant advancement in osteoporosis therapy. Angitia Biopharmaceuticals continues to lead the way in developing innovative treatments for musculoskeletal diseases, aiming to improve patient outcomes and quality of life.